Strikingly, combining LINC01559 knockdown with osimertinib (sh1-LINC01559 + Osimertinib) synergistically suppressed tumor progression, with tumors exhibiting smaller volumes (Figure 5F) and reduced weights (Figure 5G). This evidence concerns the gene LINC01559 and neoplasm.